Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor

British Journal of Pharmacology

Volumn 169, Issue 2, 2013, Pages 357-370

  Schrage, R ^a   Seemann, W K ^a   Klockner J ^b   Dallanoce, C ^c   Racke K ^a   Kostenis, E ^a   De Amici, M ^c   Holzgrabe, U ^b   Mohr, K ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

biased agonism; cell signalling; dynamic mass redistribution; efficacy; GPCRs; iperoxo; label free technologies; muscarinic ACh receptors; Superagonism

Indexed keywords

ACETYLCHOLINE; GUANINE NUCLEOTIDE BINDING PROTEIN; IPEROXO; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL STRAIN; CELL STRAIN MRC 5; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ACETYLCHOLINE; ANIMALS; CELL LINE; CHO CELLS; CRICETULUS; FIBROBLASTS; GTP-BINDING PROTEINS; HUMANS; ISOXAZOLES; LUNG; MUSCARINIC AGONISTS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTOR, MUSCARINIC M2; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84875696642     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12003     Document Type: Article

References (37)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): 1-324.
2. Antony J, Kellersohn K, Mohr-Andrae M, Kebig K, Prilla S, Muth M, et al. (2009). Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23: 442-450.
3. Black JW, Leff P, (1983). Operational models of pharmacological agonism. Proc R Soc Lond B 220: 141-162.
4. Bock A, Merten N, Schrage R, Dallanoce C, Bätz J, Klöckner J, et al. (2012). The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun 3: 1044. doi: 10.1038/ncomms2028.
5. Dallanoce C, Conti P, De Amici M, De Micheli C, Barocelli E, Chiavarini M, et al. (1999). Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. Bioorg Med Chem 7: 1539-1547.
6. Day M, Vane JR, (1963). An analysis of the direct and indirect actions of drugs on the isolated guinea-pig ileum. Br J Pharmacol Chemother 20: 150-170.
7. DeBlasi A, O'Reilly K, Motulsky HJ, (1989). Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10: 227-229.
8. Deupi X, Kobilka BK, (2010). Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 25: 293-303.
9. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK, (2007). β-Arrestins and cell signaling. Annu Rev Physiol 69: 483-510.
10. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, Kellershohn K, et al. (2006). Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 49: 366-372.
11. Engström M, Tomperi J, El-Darwish K, Ahman M, Savola JM, Wurster S, (2005). Superagonism at the human somatostatin receptor subtype 4. J Pharmacol Exp Ther 312: 332-338.
12. Gregory KJ, Hall NE, Tobin AB, Sexton PM, Christopoulos A, (2010). Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285: 7459-7474.
13. Haga K, Haga T, Ichiyama A, Katada T, Kurose H, Ui M, (1985). Functional reconstitution of purified muscarinic receptors and inhibitory guanine nucleotide regulatory protein. Nature 316: 731-733.
14. Hill SJ, Williams C, May LT, (2010). Insight into GPCR pharmacology from the measurement of changes in intracellular cyclic AMP; advantages and pitfalls of differing methodologies. Br J Pharmacol 161: 1266-1275.
15. Hobbiger F, Mitchelson F, Rand MJ, (1969). The actions of some cholinomimetic drugs on the isolated taenia of the guinea-pig caecum. Br J Pharmacol 36: 53-69.
16. Jäger D, Schmalenbach C, Prilla S, Schrobang J, Kebig A, Sennwitz M, et al. (2007). Allosteric small molecules unveil a role of an extracellular E2/transmembrane helix 7 junction for G protein-coupled receptor activation. J Biol Chem 282: 34968-34976.
17. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
18. Kennedy RH, Wyeth RP, Gerner P, Liu S, Fontenot HJ, Seifen E, (1995). Tetramethylammonium is a muscarinic agonist in rat heart. Am J Physiol 268 (6 Pt 1): C1414-C1417.
19. Klöckner J, Schmitz J, Holzgrabe U, (2010). Convergent, short synthesis of the muscarinic superagonist iperoxo. Tetrahedron Lett 51: 3470-3472.
20. Kris M, Jbilo O, Bartels CF, Masson P, Rhode S, Lockridge O, (1994). Endogenous butyrylcholinesterase in SV40 transformed cell lines: COS-l, COS-7, MRC°5 SV40, and WI-38 VA13. In Vitro Cell Dev Biol 30A: 680-689.
21. Lagerström MC, Schiöth HB, (2008). Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7: 339-357.
22. Lamyel F, Warnken-Uhlich M, Seemann WK, Mohr K, Kostenis E, Ahmedat AS, et al. (2011). The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts Naunyn Schmiedebergs Arch. Pharmacol 384: 133-145.
23. Lu ZL, Saldanha JW, Hulme EC, (2002). Seven-transmembrane receptors: crystals clarify. Trends Pharmacol Sci 23: 140-146.
24. Maloteaux JM, Hermans E, (1994). Agonist induced muscarinic cholinergic receptor internalization, recycling and degradation in cultured neuronal cells. Biochem Pharmacol 47: 77-88.
25. Matthiesen S, Bahulayan A, Kempkens S, Haag S, Fuhrmann M, Stichnote C, et al. (2006). Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 35: 621-627.
26. 2 acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br J Pharmacol 132: 1217-1228.
27. Milligan G, (2003). Principles: extending the utility of [35S]GTPγS binding assays. Trends Pharmacol Sci 24: 87-90.
28. Mistry R, Dowling MR, Challiss RAJ, (2005). An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins. Br J Pharmacol 144: 566-575.
29. Mohr K, Tränkle C, Kostenis E, Barocelli E, De Amici M, Holzgrabe U, (2010). Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 159: 997-1008.
30. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, DeWire SM, et al. (2011). Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80: 367-377.
31. Schröder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, et al. (2010). Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28: 943-949.
32. Schröder R, Schmidt J, Blättermann S, Peters L, Janssen N, Grundmann M, et al. (2011). Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protocols 6: 1748-1760.
33. Smith NJ, Bennett KA, Milligan G, (2011). When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 331: 241-247.
34. Suratman S, Leach K, Sexton PM, Felder CC, Loiacono LE, Christopoulos A, (2011). Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br J Pharmacol 162: 1659-1670.
35. Tränkle C, Kostenis E, Burgmer U, Mohr K, (1996). Search for lead structures to develop new allosteric modulators of muscarinic receptors. J Pharmacol Exp Ther 279: 926-933.
36. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, et al. (2008). A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283: 29312-29321.
37. Valant C, Lane RJ, Sexton PM, Christopoulos A, (2012). The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 52: 153-178.